ABSTRACT
Background Heart Failure (HF) and Hypertension (HTN) are common yet severe cardiovascular conditions, both of which significantly increase the risk of adverse outcomes. Patients with comorbid HF and HTN face an elevated risk of mortality. Despite the importance of early risk assessment, current ICU management strategies struggle to accurately predict mortality, limiting effective clinical interventions. To address this gap, we developed a machine learning model to predict 28-day mortality in ICU patients with HF and HTN.
Methods We extracted data from the MIMIC-IV database, identifying a cohort of 10,010 patients with both HF and HTN, among whom the 28-day mortality rate was 9.82%. The dataset was randomly split into training (70%) and testing (30%) cohorts. Feature selection was performed using a combination of the SelectKBest and Recursive Feature Elimination (RFE) wrapper methods. To address the class imbalance, we employed the Synthetic Minority Over-sampling Technique (SMOTE). Six machine learning models were developed and evaluated: Random Forest (RF), XGBoost, LightGBM, AdaBoost, Logistic Regression (LR), and a Neural Network (NN).
Results A total of 18 features were selected. The best-performing model was LightGBM, achieving an AUROC of 0.8921 (95% CI: 0.8694 - 0.9118) with a sensitivity of 0.7941 and a specificity of 0.8391 at an optimal threshold of 0.2067. External validation further demonstrated strong performance with an AUROC of 0.7404 (95% CI: 0.7130 - 0.7664).
Conclusion Our proposed model achieved an AUROC improvement of 16.8% compared to the best existing study on the same topic, while reducing the number of predictive features by 18.2%. This enhanced model underscores the potential of leveraging these selected features and our LightGBM model as a valuable tool in enhancing resource allocation and providing more personalized interventions for HF patients with HTN in ICU settings.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
